LARIAM

This brand name is authorized in Austria, Estonia, Finland, France, Malta, Netherlands, South Africa, UK.

Active ingredients

The drug LARIAM contains one active pharmaceutical ingredient (API):

1	Mefloquine UNII 5Y9L3636O3 - MEFLOQUINE HYDROCHLORIDE
	Mefloquine acts on and destroys the asexual intraerythocytic forms of the human malaria parasites: Plasmodium falciparum, P. vivax. P. malariae and P. ovale. It is effective in the treatment and prophylaxis of malaria.
	Read more about Mefloquine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LARIAM Tablets	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
P01BC02	Mefloquine	P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01B Antimalarials → P01BC Methanolquinolines
Discover more medicines within P01BC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1010091
FI	Lääkealan turvallisuus- ja kehittämiskeskus	005884
FR	Base de données publique des médicaments	65999556
GB	Medicines & Healthcare Products Regulatory Agency	147636, 21869
MT	Medicines Authority	AA565/24202
NL	Z-Index G-Standaard, PRK	25410
ZA	Health Products Regulatory Authority	28/20.2.6/0104